{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T19:10:46Z","timestamp":1757617846001,"version":"3.44.0"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,4,29]],"date-time":"2025-04-29T00:00:00Z","timestamp":1745884800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,4,29]],"date-time":"2025-04-29T00:00:00Z","timestamp":1745884800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Hematol"],"published-print":{"date-parts":[[2025,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>The co-occurrence of <jats:italic>JAK2<\/jats:italic> V617F mutations and the <jats:italic>BCR::ABL1<\/jats:italic> translocation in the same patient is rare, and the current standard treatment for aggressive myeloid blast phase chronic myeloid leukemia (CML-myeloid BP) with <jats:italic>JAK2<\/jats:italic> V617F mutations remains inadequate, particularly in transplant-ineligible patients. Asciminib, a first-in-class allosteric inhibitor of BCR::ABL1 kinase that specifically targets the ABL1 myristoyl pocket, has emerged as a novel alternative to standard tyrosine kinase inhibitor (TKI) therapy. Ropeginterferon alfa-2b (ropegIFN\u03b12b) is a novel site-selective, monopegylated recombinant human IFN with long-term safety and efficacy in patients with polycythemia vera (PV). Here, we report a case of successful combination therapy with asciminib and ropegIFN\u03b12b in a patient with CML-myeloid BP who had a long history of PV with <jats:italic>JAK2<\/jats:italic> V617F refractory to induction chemotherapy with several TKIs. The combination of asciminib and ropegIFN\u03b12b is a promising new treatment option for these patients. <\/jats:p>","DOI":"10.1007\/s12185-025-03994-2","type":"journal-article","created":{"date-parts":[[2025,4,28]],"date-time":"2025-04-28T23:06:55Z","timestamp":1745881615000},"page":"444-448","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Successful treatment of myeloid blast phase chronic myelogenous leukemia with the JAK2 V617 F mutation by combination therapy with asciminib and ropeginterferon alfa-2b in an elderly patient"],"prefix":"10.1007","volume":"122","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5405-9759","authenticated-orcid":false,"given":"Satoko","family":"Oka","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuina","family":"Akagi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takaya","family":"Mituyoshi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuo","family":"Ono","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,4,29]]},"reference":[{"issue":"12","key":"3994_CR1","doi-asserted-by":"publisher","first-page":"3445","DOI":"10.1182\/blood-2011-07-365007","volume":"118","author":"L Pieri","year":"2011","unstructured":"Pieri L, Spolverini A, Scappini B, Occhini U, Birtolo S, Bosi A, et al. Concomitant occurrence of BCR-ABL and JAK2V617F mutation. Blood. 2011;118(12):3445\u20136.","journal-title":"Blood"},{"issue":"11","key":"3994_CR2","doi-asserted-by":"publisher","first-page":"2071","DOI":"10.1007\/s00277-018-3402-x","volume":"97","author":"P Boddu","year":"2018","unstructured":"Boddu P, Chihara D, Masarova L, Pemmaraju N, Patel KP, Verstovsek S. The co-occurrence of driver mutations in chronic myeloproliferative neoplasms. Ann Hematol. 2018;97(11):2071\u201380.","journal-title":"Ann Hematol"},{"issue":"1","key":"3994_CR3","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1111\/bjh.13932","volume":"176","author":"P Martin-Cabrera","year":"2017","unstructured":"Martin-Cabrera P, Haferlach C, Kern W, Schnittger S, Haferlach T. BCR-ABL1-positive and JAK2 V617F-positive clones in 23 patients with both aberrations reveal biologic and clinical importance. Br J Haematol. 2017;176(1):135\u20139.","journal-title":"Br J Haematol"},{"issue":"9","key":"3994_CR4","doi-asserted-by":"publisher","first-page":"4106","DOI":"10.1182\/blood-2006-12-061135","volume":"109","author":"K Hussein","year":"2007","unstructured":"Hussein K, Bock O, Seegers A, Flasshove M, Henneke F, Buesche G, et al. Myelofibrosis evolving during imatinib treatment of a chronic myeloproliferative disease with coexisting BCR-ABL translocation and JAK2V617F mutation. Blood. 2007;109(9):4106\u20137.","journal-title":"Blood"},{"issue":"7","key":"3994_CR5","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1016\/S1470-2045(07)70206-1","volume":"8","author":"A Kr\u00e4mer","year":"2007","unstructured":"Kr\u00e4mer A, Reiter A, Kruth J, Erben P, Hochhaus A, M\u00fcller M, et al. JAK2-V617F mutation in a patient with Philadelphia-chromosome-positive chronic myeloid leukaemia. Lancet Oncol. 2007;8(7):658\u201360.","journal-title":"Lancet Oncol"},{"issue":"2","key":"3994_CR6","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1080\/10428190601075973","volume":"48","author":"A Quint\u00e1s-Cardama","year":"2007","unstructured":"Quint\u00e1s-Cardama A, Kantarjian H, Garcia-Manero G, O\u2019Brien S, Faderl S, Ravandi F, et al. A pilot study of imatinib, low-dose cytarabine and idarubicin for patients with chronic myeloid leukemia in myeloid blast phase. Leuk Lymphoma. 2007;48(2):283\u20139.","journal-title":"Leuk Lymphoma"},{"issue":"6","key":"3994_CR7","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1016\/j.leukres.2010.11.004","volume":"35","author":"B Deau","year":"2011","unstructured":"Deau B, Nicolini FE, Guilhot J, Huguet F, Guerci A, Legros L, et al. The addition of daunorubicin to imatinib mesylate in combination with cytarabine improves the response rate and the survival of patients with myeloid blast crisis chronic myelogenous leukemia (AFR01 study). Leuk Res. 2011;35(6):777\u201382.","journal-title":"Leuk Res"},{"issue":"18","key":"3994_CR8","doi-asserted-by":"publisher","first-page":"8120","DOI":"10.1021\/acs.jmedchem.8b01040","volume":"61","author":"J Schoepfer","year":"2018","unstructured":"Schoepfer J, Jahnke W, Berellini G, Buonamici S, Cotesta S, Cowan-Jacob SW, et al. Discovery of asciminib (ABL001), an allosteric inhibitor of the tyrosine kinase activity of BCR-ABL1. J Med Chem. 2018;61(18):8120\u201335.","journal-title":"J Med Chem"},{"issue":"8","key":"3994_CR9","doi-asserted-by":"publisher","first-page":"1825","DOI":"10.1038\/s41375-024-02320-9","volume":"38","author":"N Chatain","year":"2024","unstructured":"Chatain N, Baumeister J, Szymanski de Toledo MA, Wong DWL, Gupta S, et al. Asciminib antagonizes transplantable BCR::ABL1-positive lymphoid blast crisis in vivo by targeting malignant stem cells. Leukemia. 2024;38(8):1825\u201330.","journal-title":"Leukemia"},{"issue":"6","key":"3994_CR10","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1007\/s12185-024-03846-5","volume":"120","author":"K Kirito","year":"2024","unstructured":"Kirito K, Sugimoto Y, Gotoh A, Takenaka K, Ichii M, Inano T, et al. Long-term safety and efficacy of ropeginterferon alfa-2b in Japanese patients with polycythemia vera. Int J Hematol. 2024;120(6):675\u201383.","journal-title":"Int J Hematol"},{"issue":"5","key":"3994_CR11","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1002\/hon.2786","volume":"38","author":"S Heibl","year":"2020","unstructured":"Heibl S, Buxhofer-Ausch V, Schmidt S, Webersinke G, Lion T, Piringer G, et al. A phase 1 study to evaluate the feasibility and efficacy of the addition of ropeginterferon alpha-2b to imatinib treatment in patients with chronic phase chronic myeloid leukemia (CML) not achieving a deep molecular response (molecular remission 4.5)-AGMT_CML 1. Hematol Oncol. 2020;38(5):792\u20138.","journal-title":"Hematol Oncol"},{"issue":"6","key":"3994_CR12","doi-asserted-by":"publisher","first-page":"710","DOI":"10.5858\/arpa.2021-0096-OA","volume":"146","author":"Y Zhao","year":"2022","unstructured":"Zhao Y, Reddi D, McCracken J, Iranzad N, Rehder C, Neff J, et al. Sequential development of JAK2V617F mutation and BCR-ABL1 fusion in individual patients with myeloproliferative neoplasms. Arch Pathol Lab Med. 2022;146(6):710\u20137.","journal-title":"Arch Pathol Lab Med"},{"issue":"1","key":"3994_CR13","doi-asserted-by":"publisher","first-page":"e2021062","DOI":"10.4084\/MJHID.2021.062","volume":"13","author":"F Sora","year":"2021","unstructured":"Sora F, Chiusolo P, Autore F, Giammarco S, Laurenti L, Innocenti I, et al. Is allogeneic transplantation an option in patients affected by concurrent myelofibrosis and chronic myeloid leukemia (CML)? Mediterr J Hematol Infect Dis. 2021;13(1):e2021062.","journal-title":"Mediterr J Hematol Infect Dis"},{"issue":"22","key":"3994_CR14","doi-asserted-by":"publisher","first-page":"4391","DOI":"10.1002\/cncr.30864","volume":"123","author":"P Jain","year":"2017","unstructured":"Jain P, Kantarjian HM, Ghorab A, Sasaki K, Jabbour EJ, Nogueras Gonzalez G, et al. Prognostic factors and survival outcomes in patients with chronic myeloid leukemia in blast phase in the tyrosine kinase inhibitor era: Cohort study of 477 patients. Cancer. 2017;123(22):4391\u2013402.","journal-title":"Cancer"},{"issue":"9","key":"3994_CR15","first-page":"981","volume":"64","author":"N Takahashi","year":"2023","unstructured":"Takahashi N. Next treatment for TKI-resistant CML. Rinsho Ketsueki. 2023;64(9):981\u20137.","journal-title":"Rinsho Ketsueki"},{"key":"3994_CR16","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.gene.2018.11.005","volume":"686","author":"RK Chandran","year":"2019","unstructured":"Chandran RK, Geetha N, Sakthivel KM, Aswathy CG, Gopinath P, Raj TVA, et al. Genomic amplification of BCR-ABL1 fusion gene and its impact on the disease progression mechanism in patients with chronic myelogenous leukemia. Gene. 2019;686:85\u201391.","journal-title":"Gene"},{"issue":"7","key":"3994_CR17","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.3109\/10428194.2013.845883","volume":"55","author":"EJ Jabbour","year":"2014","unstructured":"Jabbour EJ, Hughes TP, Cort\u00e9s JE, Kantarjian HM, Hochhaus A. Potential mechanisms of disease progression and management of advanced-phase chronic myeloid leukemia. Leuk Lymphoma. 2014;55(7):1451\u201362.","journal-title":"Leuk Lymphoma"},{"issue":"21","key":"3994_CR18","doi-asserted-by":"publisher","first-page":"2031","DOI":"10.1182\/blood.2020009984","volume":"138","author":"D R\u00e9a","year":"2021","unstructured":"R\u00e9a D, Mauro MJ, Boquimpani C, Minami Y, Lomaia E, Voloshin S, et al. A phase 3, open-label, randomized study of asciminib, a STAMP inhibitor, vs bosutinib in CML after 2 or more prior TKIs. Blood. 2021;138(21):2031\u201341.","journal-title":"Blood"},{"issue":"10","key":"3994_CR19","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1056\/NEJMoa2400858","volume":"391","author":"A Hochhaus","year":"2024","unstructured":"Hochhaus A, Wang J, Kim DW, Kim DDH, Mayer J, Goh YT, et al. Asciminib in newly diagnosed chronic myeloid leukemia. N Engl J Med. 2024;391(10):885\u201398.","journal-title":"N Engl J Med"},{"issue":"6","key":"3994_CR20","doi-asserted-by":"publisher","first-page":"1643","DOI":"10.1038\/s41375-020-01020-4","volume":"35","author":"JP Bewersdorf","year":"2021","unstructured":"Bewersdorf JP, Giri S, Wang R, Podoltsev N, Williams RT, Tallman MS, et al. Interferon alpha therapy in essential thrombocythemia and polycythemia vera-a systematic review and meta-analysis. Leukemia. 2021;35(6):1643\u201360.","journal-title":"Leukemia"},{"issue":"3","key":"3994_CR21","doi-asserted-by":"publisher","first-page":"e196","DOI":"10.1016\/S2352-3026(19)30236-4","volume":"7","author":"H Gisslinger","year":"2020","unstructured":"Gisslinger H, Klade C, Georgiev P, Krochmalczyk D, Gercheva-Kyuchukova L, Egyed M, et al. Ropeginterferon alfa-2b versus standard therapy for polycythaemia vera (PROUD-PV and CONTINUATION-PV): a randomised, non-inferiority, phase 3 trial and its extension study. Lancet Haematol. 2020;7(3):e196\u2013208.","journal-title":"Lancet Haematol"},{"issue":"10","key":"3994_CR22","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.1038\/s41375-023-02008-6","volume":"37","author":"H Gisslinger","year":"2023","unstructured":"Gisslinger H, Klade C, Georgiev P, Krochmalczyk D, Gercheva-Kyuchukova L, Egyed M, et al. Event-free survival in patients with polycythemia vera treated with ropeginterferon alfa-2b versus best available treatment. Leukemia. 2023;37(10):2129\u201332.","journal-title":"Leukemia"},{"issue":"6","key":"3994_CR23","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1016\/S1470-2045(18)30192-X","volume":"19","author":"S Saussele","year":"2018","unstructured":"Saussele S, Richter J, Guilhot J, Gruber FX, Hjorth-Hansen H, Almeida A, et al. Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial. Lancet Oncol. 2018;19(6):747\u201357.","journal-title":"Lancet Oncol"}],"container-title":["International Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-025-03994-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12185-025-03994-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-025-03994-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,6]],"date-time":"2025-09-06T12:48:04Z","timestamp":1757162884000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12185-025-03994-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,29]]},"references-count":23,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["3994"],"URL":"https:\/\/doi.org\/10.1007\/s12185-025-03994-2","relation":{},"ISSN":["0925-5710","1865-3774"],"issn-type":[{"type":"print","value":"0925-5710"},{"type":"electronic","value":"1865-3774"}],"subject":[],"published":{"date-parts":[[2025,4,29]]},"assertion":[{"value":"6 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 April 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 April 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 April 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All the authors declare no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The patients provided their written informed consent to receive each regimen, and treatment was administered according to the principles of the Declaration of Helsinki. This study was approved by the Japanese Red Cross Society Wakayama Medical Center ethics committee.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all the individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Patient signed informed consent regarding publishing their data and images.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}}]}}